Taxanes for advanced non-small cell lung cancer

REFERENCES

• MOUNTAIN CE DRESLER CM: Regional lymph node classification for lung cancer staging. Chest (1997) 111:1718–1723.
   PubMedGoogle Scholar
• NSCLC Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br. Med. J. (1995) 311:899–909.
   PubMedGoogle Scholar
• •This meta-analysis demontrated benefit with platinum-based chemotherapy for patients with advanced NSCLC.
   Google Scholar
• SANDLER A, ETTINGER DS: Gemcitabine: single-agent and combination therapy in NSCLC. Oncologist (1999) 4:241–251.
   PubMedGoogle Scholar
• CRAWFORD J, O'ROURKE M, SCHILLER JH et a/.: Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer.! Clin. Oncol (1996) 14:2774–2784.
   Google Scholar
• DEPIERRE A, LEMARIE E, DABOUIS G et al.: A Phase II study of navelbine (vinorelbine) in the treatment of non-small cell lung cancer. Am. J. Clin. Oncol (1991) 14:115–119.
   PubMed Web of Science ®Google Scholar
• DOUILLARD FY, IBRAHIM N, RIVIERE A et al.: Phase II study of CPT-11 (irinotecan) in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (1995) 14:365a.
   Google Scholar
• RAMANATHAN RK, BELANI CP: Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin.Oncol (1997) 24:440–454.
   PubMed Web of Science ®Google Scholar
• SCHILLER J, HARRINGTON D, BELANI CP et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl. I Med. (2002) 346:92–98.
   PubMed Web of Science ®Google Scholar
• •Large clinical trial that demonstrated comparable efficacy between four commonly used chemotherapy regimens for the treatment of NSCLC.
   Google Scholar
• RODRIGUEZ J, PAWEL J, PLUZANSKA A et al.: A multicenter, randomized Phase III study of docetaxel+ cisplatin (DC) and docetaxel + carboplatin (DCB) versus vinorelbine + cisplatin (VC) in chemotherapy-naive patients with advacned and metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol (2001) 20:314a.
   Google Scholar
• •This three-arm study established the docetaxel-platinum combination as an effective regimen for the treatment of advanced NSCLC.
   Google Scholar
• KELLY K, CROWLEY J, BUNN PA et al: Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. I. Clin. Oncol (2001) 19:3210–3218.
   PubMed Web of Science ®Google Scholar
• •The trial demonstrated comparable efficacy and a more favorable toxicity profile for the carboplatin-paclitaxel regimen over cisplatin-vinorelbine.
   Google Scholar
• BELANI CP, NATALE RB, LEE JS et al: Randomized Phase III trial comparing cisplatin/etoposide versus carboplatin/ paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol (1998) 17:455a.
   Google Scholar
• •First randomised trial to establish the efficacy of carboplatin-paclitaxel as first-line therapy for advanced NSCLC.
   Google Scholar
• WANI MC, TAYLOR HL, WALL ME et al.: Plant antitumor agents: VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am. Chem. Soc. (1971) 93:2325–2327.
   Google Scholar
• VERWEIJ J, CLAVEL M, LE CHEVALIER B: Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann. Oncol. (1994) 5:495–505.
   PubMed Web of Science ®Google Scholar
• EISENHAUER EA, VERMORKEN JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs (1998) 55:5–30.
   Google Scholar
• LIEBMANN J, COOK JA, LIPS CHULTZ C et al.: Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J. Cancer (1993) 68:1104–1109.
   Google Scholar
• AOE K, UEOKA H, KIURA K et al: Synergistic effect of docetaxel and vinorelbine against in vitro growth of a human small-cell lung cancer cell line. Proc. Ann. Mtg. Am. Assoc. Cancer. Res. (1996) 37:1780a.
   Google Scholar
• MILAS L, MILAS MM, MANSON KA: Combination of taxanes with radiation: preclinical studies. Sem. Radiat. Omni (1999) 9\(Suppl. 1):12–26.
   Google Scholar
• VACCA A, RIBATTI D, IURLARO M et al.: Docetaxel versus paclitaxel for antiangiogenesis. J Hematother. Stem Cell Res. (2002) 11:103–118.
   PubMedGoogle Scholar
• ROWINSKY E, ONETTO N, CANETTA RM et al.: Taxol: the prototypic taxane, an important new class of antitumor agents. Semin. Omni (1992) 19:646–662.
   Google Scholar
• ROWINSKY EK, EISENHAUER EA, CHAUDHRY V: Clinical toxicities encountered with paclitaxel (Taxol). Semin. Oncol. (1993) 20:1–15.
   PubMed Web of Science ®Google Scholar
• GELDERBLOM H, MROSS K, TEN TIJE Al et al.: Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions. J. Clin. Oncol. (2002) 20:574–581.
   Google Scholar
• GRECO FA: Docetaxel (Taxotere) administered in weekly schedules. Semin. Oncol. (1999) 26\(Suppl. 11):28–31.
   Google Scholar
• GALINDO E, KAVANAGH J, FOSSELLA F et al.: Docetaxel toxicities: analysis of a single institution experience of 168 patients (623 courses). Proc. Am. Soc. Clin. Omni (1994) 13:164a.
   Google Scholar
• CHANG AY, KIM K, GLICK J et al: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group results. Natl. Cancer Inst. (1993) 85:388–394.
   Google Scholar
• MURPHY WK, FOSSELLA FV, WINN RI et al.: Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. Natl. Cancer Inst. (1993) 85:384–388.
   Google Scholar
• GATZEMEIER U, HECKMAYR M, NEUHAUSS R et al.: Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer (1995) 12:S101–S106.
   Google Scholar
• TESTER W, JIN PY, REARDON DH et al.: Phase II study of patients with metastatic non small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer (1997) 79:724–729.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, THOMPSON DS, GRECO FA et al: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. Clin. Omni (1995) 13:1609–1614.
   PubMed Web of Science ®Google Scholar
• PANS ON M, DAVIDSON N, NICOLSON M et al.: Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl. Cancer Inst. (2000) 92:1074–1080.
   PubMedGoogle Scholar
• •This is the only randomised trial that has compared a taxane to best supportive care for patients with previously untreated advanced NSCLC.
   Google Scholar
• BREATHNACH OS, GEORGIADIS MS, SCHULER BS et al.: Phase II trial of paclitaxel by 96-hour continuous infusion in combination with cisplatin for patients with advanced non-small cell lung cancer. Clin. Cancer Res. (2000) 6:2670–2676.
   PubMed Web of Science ®Google Scholar
• GEORGIADIS MS, RUSSELL EK, GAZDAR AF et al.: Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. Clin. Cancer Res. (1997) 3:449–454.
   PubMed Web of Science ®Google Scholar
• BELANI CP, VAN ECHO DA, AISNERJ: Platinum compounds. Current Opin. Omni (1989) 1:186–191.
   PubMedGoogle Scholar
• BELANI CP, KEARNS CM, ZUHOWSKI EG et al.: A Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small cell lung cancer. Clin. Oncol. (1999) 17:676–684.
   Google Scholar
• LANGER CI, LEIGHTON JC, COMISRL et al.: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A Phase II toxicity, response, and survival analysis. J. Clin. Oncol. (1995) 13:1860–1870.
   PubMed Web of Science ®Google Scholar
• KEARNS C, BELANI CP, HIPONIA D et al.: Pharmacology of carboplatin and paclitaxel. Semin. Omni (1995) 22:1–6.
   Google Scholar
• GATZEMEIER U, VON PAWEL J, GOTTFRIED M et al.: Phase III comparative study of high-dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced non-small-cell lung cancer. J Clin. Oncol. (2000) 18:3390–3399.
   PubMed Web of Science ®Google Scholar
• •This study demonstrated that the platinum-based two drug combination is superior in efficacy to therapy with platinum alone for patients with advanced NSCLC.
   Google Scholar
• GIACCONE G, SPLINTER TA, DEBRUYNE C et al.: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Lung Cancer Cooperative Group. J Clin. Omni (1998) 16:2133–2141.
   Google Scholar
• •Phase III trial that confirmed the efficacy of cisplatin-paclitaxel in the treatment of advanced NSCLC.
   Google Scholar
• LILENBAUM R, HERNDON LIST M et al: Single agent versus combination chemotherapy in advanced non-small cell lung cancer: a CALGB randomized trial of efficacy, quality of life, and cost-effectiveness. Proc. Am. Soc. Clin. Omni (2002) 21:1a.
   Web of Science ®Google Scholar
• •Randomised Phase III study that demonstrated that platinum is an essential component of doublet regimens for the treatment of advanced NSCLC.
   Google Scholar
• KELLY K, PAN Z, MURPHY J et al.: A Phase I trial of paclitaxel plus carboplaitn in untreated patients with advanced non-small cell lung cancer. Clin. Cancer Res. (1997) 3:1117–1123.
   PubMed Web of Science ®Google Scholar
• HUIZING MT, VAN WARMERDAM LIC, ROSING H et al: Phase land pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage IIIB or IV ovarian cancer. J. Clin. Omni (1997) 15:1953–1964.
   PubMed Web of Science ®Google Scholar
• BONOMI P, KIM K, FAIRCLOUGH D et al.: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an eastern cooperative oncology group trial. J. Clin. Oncol. (2000) 18:623–631.
   PubMed Web of Science ®Google Scholar
• •Large randomised trial that established the efficacy of cisplatin-paclitaxel for the treatment of advanced NSCLC.
   Google Scholar
• ROWINSKY EK, JIROUTEK M, BONOMI P et al.: Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin. Gin. Cancer Res. (1999) 5:767–774.
   Google Scholar
• •Efficacy of the cisplatin-paclitaxel regimen was not influenced by steady-state plasma concentration of paclitaxel in patients with advanced NSCLC.
   Google Scholar
• KOSMIDIS P, MYLONAKIS N, SKARLOS D et al: Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann. Oncol. (2000) 11:799–805.
   PubMed Web of Science ®Google Scholar
• •The only randomised trial to compare two dose-levels of paclitaxel in combination with carboplatin for patients with advanced NSCLC.
   Google Scholar
• CHOY H, PYO H, KIM JS et al.: Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer. Expert Opin. Pharmacother. (2001) 2:963–974.
   PubMedGoogle Scholar
• AKERLEY W, GLANTZ M, CHOY H et al.: Phase I trial of weekly paclitaxel in advanced lung cancer.Oncol. (1998)16:153–158.
   Google Scholar
• AKERLEY W, HERNDON J, EGORIN MJ et al.: Phase II trial of weekly paclitaxel for advanced non-small cell lung cancer. Proc. Am. Soc. Gin. Oncol. (1999) 18:462a.
   Google Scholar
• BELANI CP, BARSTIS J, PERRY M et al.: Phase II multicenter randomized trial of weekly paclitaxel administered in combination with carboplatin followed by maintenance paclitaxel versus observation for patients with advanced and metastatic non-small cell lung cancer. Proc. Am. Soc. Oncol. (2001) 20:323a.
   Google Scholar
• SOCINSKI MA, SCHELL MJ, BAKRI K et al.: Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel. Cancer (2002) 95:1265–1273.
   PubMed Web of Science ®Google Scholar
• SCULIER JP, BERGHMANS T, LAFITTE JJ et al.: A Phase II study testing paclitaxel as second-line single agent treatment for patients with advanced non-small cell lung cancer failing after a first-line chemotherapy. Lung Cancer (2002) 37:73–77.
   PubMed Web of Science ®Google Scholar
• KOUMAKIS G, DEMETRI M, BARBOUNIS V et al: Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a Phase II trial. Lung Cancer (2002) 35:315–317.
   PubMed Web of Science ®Google Scholar
• ROA V, CONNER A, MITCHELL RB et al.: Carboplatin and paclitaxel for previously treated patients with non-small cell lung cancer. Cancer Invest. (1998) 16:381–384.
   PubMed Web of Science ®Google Scholar
• STATHOPOULOS GP, RIGATOS S, MALAMOS NA et al.: Paclitaxel combined with cisplatin as second-line treatment in patients with advanced non-small cell lung cancers refractory to cisplatin. Oncol. Rep. (1999) 6:797–800.
   PubMed Web of Science ®Google Scholar
• KAVALLARIS M, KUO DYS, BURKHARDT CA et al.: Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific 13-tubulin isotypes. Clinical Invest. (1997) 100:1282–1293.
   Google Scholar
• ZAMAN GJR, FLENS MJ, VAN LEUSDEN HR et al.: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sd. USA (1994) 91:8822–8826.
   Google Scholar
• MONZO M, ROSELL R, SANCHEZ J et al.: Paclitaxel resistance in non-small-cell lung cancer associated with 13-tubulin gene mutations. I Clin. Oncol. (1999) 17:1786–1793.
   PubMed Web of Science ®Google Scholar
• •Interesting study that demonstrated decreased response to therapy with paclitaxel in patients who had mutations at the 13-tubulin gene.
   Google Scholar
• EISENHAUER EA, LU F, MULDAL A et al.: Predictors and treatment of docetaxel toxic effects. Ann. Oncol. (1994)\(Suppl. 5):202.
   Google Scholar
• RAMALINGAM S, BONOMI P, DOBBS T et al.: Docetaxel and carboplatin for advanced non-small cell lung cancer: Dose of carboplatin influences outcome. Proc. Am. Soc. Clin. Oncol. (2002) 21:316a.
   Google Scholar
• GRALLA RJ, RODRIGUEZ J, VON PAWEL J et al.: Prospective analysis of quality of life (Q0L) in a randomized multinational Phase III study comparing docetaxel (D) plus either cisplatin (C) or carboplatin (Cb) with vinorelbine plus cisplatin (VC) in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2002) 21:300a.
   Google Scholar
• •Phase III study performed in Japan documented the efficacy of cisplatin-docetaxel as first-line therapy for advanced NSCLC.
   Google Scholar
• KUBOTA K, WATANABE K, KUNITOH H et al.: Final results of a randomized Phase III trial of docetaxel and cisplatin versus vindesine and cisplatin in stage IV non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. (2002) 21:296a.
   Google Scholar
• GEORGOULIAS V, ARDAVANIS A, AGELIDOU M et al.: Preliminary analysis of a multicenter Phase III trial comparing docetaxel versus docetaxel/cisplatin in patients with inoperable advanced and metastatic non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. (2002) 21:291a.
   Google Scholar
• SEDERHOLM C: Gemcitabine compared with gemcitabine plus carboplatin in advanced non-small cell lung cancer: a Phase III study by the Swedish Lung Cancer Study Group. Proc. Am. Soc. Clin. Oncol. (2002) 21:291a.
   Google Scholar
• FERRIGNO D, BUCCHERI G: Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference? Lung Cancer (2000) 29:91–104.
   PubMed Web of Science ®Google Scholar
• SHEPHERD FA, DANCEY J, RAMLAU R et al.: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. j. Clin. Oncol. (2000)18:2095–2103.
   PubMed Web of Science ®Google Scholar
• •This trial established docetaxel as an effective second-line agent in the treatment of advanced NSCLC.
   Google Scholar
• FOSSELLA FV, DEVORE R, KERR RN et al.: Randomized Phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. Clin. Oncol. (2000) 18:2354–2362.
   Web of Science ®Google Scholar
• •Another Phase III trial that confirmed the efficacy of docetaxel as a second-line agent for the treatment of advanced NSCLC.
   Google Scholar
• GANDARA DR, VOKES E, GREEN M et al.: Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a Phase II multicenter trial. J. Clin. Oncol. (2000) 18:131–135.
   PubMed Web of Science ®Google Scholar
• LILENBAUM RC, SCHWARTZ MA, SEIGEL L et al.: Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma. Cancer (2001) 92:2158–2163.
   PubMed Web of Science ®Google Scholar
• HAINSWORTH JD, BURRIS HA, LITCHY S et al.: Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer (2000) 89:328–333.
   Google Scholar
• GERVAIS R, DUCOLONE AMD, BRETON JL et al.: Multicenter randomized Phase II trial of docetaxel 75 mg/m2 q.3.weeks versus 40 mg/m2 weekly in patients with pretreated non small cell lung cancer. Proc. Am. Soc. Clin. Oncol (2002) 21:310a.
   Google Scholar
• SCHUTTE W, NAGEL S, LAUTENSCHLAGER C et al.: Randomized Phase III study of weekly versus three-weekly docetaxel as second-line chemotherapy for advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Omni (2002) 21:308a.
   Google Scholar
• GEORGOULIAS V, PAPADAKIS E, ALEXOPOULOS A et al.: Platinum-based and non-platinum-based chemotherapy in advanced non-small cell lung cancer: a randomized multicenter trial. Lancet (2001) 357:1478–1484.
   PubMed Web of Science ®Google Scholar
• •This randomised Phase II study demonstrated comparable efficacy for a non-platinum regimen when compared to a platinum-based two drug combination for the treatment of advanced NSCLC.
   Google Scholar
• VAN MEERBEECK J, SMIT EF, LIANES P et al.: A EORTC randomized Phase III trial of three chemotherapy regimens in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Omni (2001) 20:308a.
   Google Scholar
• •Study shows trend towards decreased efficacy for non-platinum regimens in the treatment of advanced NSCLC.
   Google Scholar
• KOSMIDIS P, MYLONAKIS N, NICOLAIDES C et al.: Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a Phase III randomized trial." Clin. Oncol (2002) 20:3578–3585.
   Google Scholar
• CHEN YM, PERNG R, LEE YC et al: Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized Phase II study of combination chemotherapy against inoperable non-small cell lung cancer previously untreated. Ann. Omni (2002)13:108–115.
   Google Scholar
• TRUMP DL, EGORIN MJ, RAMANATHAN R et al: A new oral taxane (BMS 275183): Phase I trial with evaluation of pharmacokinetics, pharmacodynamics and bioavailability. Proc. Am. Soc. Clin. Oncol (2002) 21:100a.
   Google Scholar
• ALBEROLA V, ROSELL R, GONZALEZ- LARRIBA JL et al.: Single agent taxol, 3-hour infusion, in untreated advanced non-small cell lung cancer. Ann. Oncol (1995) 6:S49–S52.
   Google Scholar
• MILLWARD MJ, BISHOP JF, FRIEDLANDER M et al.: Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small cell lung cancer. Clin. Oncol (1996) 14:142–148.
   Google Scholar
• HAINSWORTH JD, THOMPSON DS, GRECO FA et al: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer." Clin. Omni (1995) 13:1609–1614.
   PubMed Web of Science ®Google Scholar
• MILLER VA, RIGAS JR, FRANCIS PA et al.: Phase II trial of a 75 mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer (1995) 75:968–972.
   PubMed Web of Science ®Google Scholar
• LATREILLE J, GELMON KA, HIRSH V et al.: Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest. New Drugs (1998) 16:265–270.
   PubMedGoogle Scholar
• CERNY T, KAPLAN S, PAVLIDIS N et al.: Docetaxel (Taxotere) is active in non-small cell lung cancer: a Phase II trial of the EORTC Early Clinical Trials Group (ECTG). Br. Cancer (1994) 70:384–387.
   Google Scholar
• FRANCIS PA, RIGAS JR, KRIS MG et al.: Phase II trial of docetaxel in patients with stage III and IV non-small cell lung cancer. Clin. Oncol (1994) 12:1232–1237.
   Google Scholar
• FOSSELLA FV, LEE JS, MURPHY WK et al.: Phase II study of docetaxel for recurrent or metastatic non-small cell lung cancer.j Clin. Omni (1994)12:1238–1244.
   PubMed Web of Science ®Google Scholar
• KUNITOH H,WATANABE K, ONOSHI T et al: Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. " Clin. Omni (1996) 14:1649–1655.
   PubMed Web of Science ®Google Scholar
• PERNG RP, SHIH JF, CHEN YM et al.:A Phase II study of single-agent docetaxel chemotherapy for non-small cell lung cancer. fpn. Clin. Oncol (2000) 30:429–434.
   Google Scholar
• SAARINEN A, JEKUNEN A, HALME M et al.: A Phase II trial of docetaxel in advanced non-small cell lung cancer. Anti-Drugs (1996) 7:890–892.
   PubMedGoogle Scholar
• GRIDELLI C, FRONTINI L, BARLETTA E et al: Single agent docetaxel plus granulocyte-colony stimulating factor (G-CSF) in previously treated patients with advanced non small cell lung cancer. A Phase II study and review of the literature. Anticancer Res. (2000) 20:1077–1084.
   PubMedGoogle Scholar
• MATTSON K, BOSQUEE L, DABOUIS G et al.: Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice. Lung Cancer (2000) 29:205–216.
   PubMed Web of Science ®Google Scholar
• FOSSELLA FV, LEE JS, SHIN DM et al:Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. " Clin. Oncol (1995) 13:645–651.
   PubMed Web of Science ®Google Scholar
• PIRKER R, KRAJNIK G, ZOCHBAUER S et al.: Paclitaxel/cisplatin in advanced non-small cell lung cancer (NSCLC). Ann. Omni (1995) 6:833–835.
   Google Scholar
• VON PAWEL J, WAGNER H, NIEDERLE N et al: Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin. Omni (1996) 23:S47–S50.
   Google Scholar
• HSU JW, HSU JY, CHIANG CD: Preliminary result of Phase II study of paclitaxel and cisplatin chemotherapy for advanced non-small cell lung cancer in chinese patients. Am. .1 Chit. Omni (1998) 21:487–490.
   PubMed Web of Science ®Google Scholar
• SAKAI H, YONEDA S, TAMURA T et al.: A Phase II study of paclitaxel plus cisplatin for advanced non-small cell lung cancer in Japanese patients. Cancer Chemother: Pharmacol (2001) 48:499–503.
   PubMedGoogle Scholar
• SORENSEN JB, WEDERVANG K, DOMBERNOWSKY P et al.: Preliminary results of a Phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer. Semin. Oncol (1997) 24:S12–S18.
   Google Scholar
• BELLI L, LE CHEVALIER T, GOTTFRIED M et al.: Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Omni (1995) 14:1058a.
   Google Scholar
• JOHNSON DH, PAUL DM, HANDE KR et al.: Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A Phase II trial. Clin. Oncol (1996) 14:2054–2060.
   Google Scholar
• HAINSWORTH JD, URBA WJ, HON JKet al.: One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter, Phase II trial. Eur:.1. Cancer (1998) 34:654–658.
   Google Scholar
• LAOHAVINIJ 5, MAOLEEKOONPAIROJ S, CHEIRSILPA A et al.: Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer. Lung Cancer (1999) 26:175–185.
   Google Scholar
• CHEN YM, PERNG RP, LEE YC et al.: Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized Phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated. Ann. Oncol (2002) 13:108–115.
   PubMedGoogle Scholar
• KOSMIDIS PA, MYLONAKIS N, FOUNTZILAS G et al.: Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a Phase II study. Ann. Oncol (1997) 8:697–699.
   PubMed Web of Science ®Google Scholar
• SCAGLIOTTI G, CRINO L, POZZI E et al.: Phase I/II dose finding study of paclitaxel and carboplatin in advanced non-small cell lung cancer. Lung Cancer (1999) 25:39–46.
   PubMed Web of Science ®Google Scholar
• LANGER CJ, LEIGHTON JC, COMIS RL et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A Phase II toxicity, response, and survival analysis. Cilia. Oncol (1995) 13:1860–1870.
   PubMed Web of Science ®Google Scholar
• BELANI CP, KEARNS CM, ZUHOWSKI EG et al.: A Phase I trial, including pharmacolkinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small cell lung cancer. Clin. Oncol (1999) 17:676–684.
   Google Scholar
• MUGGIA FM, VAFAI D, NATALE R: Paclitaxel 3-hour infusion given alone and combined with carboplatin: preliminary results of dose-escalation trials. Semin. Omni (1995) 22:63–66.
   Google Scholar
• HELSING M, THANING, L, SEDERHOLM C et al.: Treatment with paclitaxel 1-h infusion and carboplatin of patients with advanced non-small-cell lung cancer: a Phase II multicentre trial. Joint Lung Cancer Study Group. Lung Cancer (1999) 24:107–113.
   PubMedGoogle Scholar
• ZALCBERG J, MILLWARD M, BISHOP Jet al.: Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. Cilia. Omni (1998) 16:1948–1953.
   Google Scholar
• BELANI CP, BONOMI P, DOBBS TW, et al.: Docetaxel and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC): a multicenter Phase II trial. Clin. Lung Cancer (1999) 1:144–150.
   Google Scholar
• GEORGOULIAS V, ANDROULAKIS N, DIMOPOULOS AM et al.: First-line treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin: a multicenter Phase II study. Ann. Omni (1998) 9:331–334.
   Google Scholar
• LE CHEVALIER T, MONNIER A, DOUILLARD JY et al.: Docetaxel (Taxotere) plus cisplatin: an active and well-tolerated combination in patients with advanced non-small cell lung cancer. Eur. Cancer (1998) 34:2032–2036.
   PubMed Web of Science ®Google Scholar
• SCHUETTE W, BORK I, WOLLSCHLAGER B et al: Combination chemotherapy with docetaxel and carboplatin for advanced non-small cell lung cancer. Cilia. Drug Invest. (2001) 21:161–168.
   PubMedGoogle Scholar
• MILLWARD MJ, BISHOP J, LEHNERT M et al.: Phase II trial of docetaxel and carboplatin in advanced NSCLC. Proc. Am. Soc. Clin. Omni (1999) 18:517a.
   Google Scholar
• ARCENAS A, ANDERSON A, KRASNOW S et al.: Docetaxel/carboplatin combination therapy for stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Omni (1999) 18:495a.
   Google Scholar
• HARVEY J, WINDSOR K, LASKER J et al.: A Phase II study of docetaxel and carboplatin in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Omni (2000) 19:511a.
   Google Scholar
• JAHANZEB M, SARNA G, HIRSCH R et al.: A multicenter Phase II trial of carboplatin and docetaxel in previously untreated advanced non-small cell lung carcinoma. Proc. Am. Soc. Clin. Omni (2000) 19:514a.
   Google Scholar